Discovery of direct-acting small-molecule RIG-I agonists through creation of a selective CARD activation platform

Rong Guo, Kenneisha Norford, Ling Xu, Manyi Wei, Wenshuai Wang, Stephanie Halene, Anna Marie Pyle · 2026

Read Discovery of direct-acting small-molecule RIG-I agonists through creation of a selective CARD activation platform by Rong Guo, Kenneisha Norford, Ling Xu, Manyi Wei, Wenshuai Wang, Stephanie Halene, Anna Marie Pyle (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13680500.txt.

Description

Rong Guo and co-authors report the first small-molecule drugs that switch on RIG-I, an antiviral sensor, in this 2026 study. RIG-I spots RNA viruses and starts the body's defense, making it a prized drug target. Existing activators are RNA strands, which the body handles poorly as medicines. Small molecules could travel better, but none directly fired the sensor before this work.

The team built a sensitive screening test that watches the sensor's signaling arms pop free, the first step of activation. Screening found hits, which they refined into a specific activator. The refined compound triggered a strong interferon response in tests. The study delivers both an assay and a chemical starting point for drugs that tune this immune pathway.

Catalog record

CREATORRong Guo, Kenneisha Norford, Ling Xu, Manyi Wei, Wenshuai Wang, Stephanie Halene, Anna Marie Pyle
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE75 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13680500

Browse the full library · About the Tower of Babel